Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

Novo Nordisk's cash-pay offering will expand access to eligible Type 2 diabetes patients who don't have insurance coverage for the weekly injection. In March, the company began to offer Wegovy for half its list price to cash-paying Americans. Patients can pay $499 in cash per month for three dose sizes of Ozempic. They can get the price through platforms including the drug's official website, Novo Nordisk's patient assistance program and the company's recently launched direct-to-consumer online pharmacy, th ...